Ubs Asset Management Americas Inc Madrigal Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 27,538 shares of MDGL stock, worth $9.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,538
Previous 22,356
23.18%
Holding current value
$9.25 Million
Previous $4.74 Million
79.11%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding MDGL
# of Institutions
335Shares Held
22.3MCall Options Held
960KPut Options Held
940K-
Janus Henderson Group PLC London, X02.21MShares$741 Million0.36% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$686 Million38.14% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$681 Million9.12% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$669 Million10.03% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$663 Million6.75% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.74B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...